Getinge (BATS-CHIXE:GETIBS) - Stock Price, News & Analysis

GETIBS Stock Overview

Provides products and solutions for operating rooms, intensive-care units, and sterilization departments.

GETIBS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 40% below our estimate of its fair value

Earnings are forecast to grow 12.37% per year

Earnings have grown 10.4% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Getinge AB (publ) Competitors

Smith & Nephew

LSE:SN.

UK£10.0b

NIOX Group

AIM:NIOX

UK£279.9m

ConvaTec Group

LSE:CTEC

UK£4.5b

EKF Diagnostics Holdings

AIM:EKF

UK£129.3m

Price History & Performance

Summary of all time highs, changes and price drops for Getinge
Historical stock prices
Current Share Price	SEK 222.10
52 Week High	SEK 231.75
52 Week Low	SEK 179.45
Beta	0.47
11 Month Change	5.99%
3 Month Change	n/a
1 Year Change	11.58%
33 Year Change	-41.43%
5 Year Change	60.71%
Change since IPO	21.43%

Recent updates

Shareholder Returns

	GETIBS	GB Medical Equipment	GB Market
7D	0%	-4.0%	-0.7%
1Y	11.6%	4.8%	6.7%

Return vs Industry: GETIBS exceeded the UK Medical Equipment industry which returned 4.8% over the past year.

Return vs Market: GETIBS exceeded the UK Market which returned 6.7% over the past year.

Price Volatility

Is GETIBS's price volatile compared to industry and market?
GETIBS volatility
GETIBS Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: GETIBS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GETIBS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1904	11,891	Mattias Perjos	www.getinge.com

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.

Getinge AB (publ) Fundamentals Summary

How do Getinge's earnings and revenue compare to its market cap?
GETIBS fundamental statistics
Market cap	SEK 62.24b
Earnings (TTM)	SEK 2.58b
Revenue (TTM)	SEK 33.33b

23.7x

P/E Ratio

1.8x

P/S Ratio

Is GETIBS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GETIBS income statement (TTM)
Revenue	SEK 33.33b
Cost of Revenue	SEK 17.91b
Gross Profit	SEK 15.42b
Other Expenses	SEK 12.84b
Earnings	SEK 2.58b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 18, 2024

Earnings per share (EPS)	9.49
Gross Margin	46.27%
Net Profit Margin	7.75%
Debt/Equity Ratio	21.6%

How did GETIBS perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

46%

Payout Ratio

GETIBS Stock Overview

Rewards

Risk Analysis

Getinge AB (publ) Competitors

LSE:SN.

UK£10.0b

AIM:NIOX

UK£279.9m

LSE:CTEC

UK£4.5b

AIM:EKF

UK£129.3m

Price History & Performance

Recent News & Updates

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

First quarter 2024 earnings released: EPS: kr1.69 (vs kr2.15 in 1Q 2023)

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Dividend increased to kr4.40

Recent updates

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

First quarter 2024 earnings released: EPS: kr1.69 (vs kr2.15 in 1Q 2023)

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Second quarter 2023 earnings released: EPS: kr0.79 (vs kr2.21 in 2Q 2022)

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

New minor risk - Dividend sustainability

Investor sentiment deteriorates as stock falls 22%

Now 21% undervalued

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Now 20% undervalued

First quarter 2023 earnings released

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Investor sentiment deteriorated over the past week

Getinge Revises Net Sales Guidance for the Full Year 2022

Investor sentiment deteriorated over the past week

Insider recently bought kr502k worth of stock

Insufficient new directors

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)

Insufficient new directors

President of Acute Care Therapies recently bought kr486k worth of stock

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Now 21% undervalued after recent price drop

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Chief Financial Officer recently bought kr467k worth of stock

Insider recently bought kr388k worth of stock

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)

Getinge AB Provides Sales Guidance for the Year 2021

Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency